Stay up to date with our newsletter

Get in touch!

What can we do to help?

I would like to:

Lets start the conversation!

Sign up to our newsletter

View open positions on our Careers page,
or connect with us on Linkedin Twitter Facebook

Thank you!
We will be in touch shortly.

2020.01.10

Dr. Mark Bittinger joins Sai Life Sciences as Global Head of Biology

Dr. Mark Bittinger

Sai Life Sciences, one of India’s fastest growing Contract Development & Manufacturing Organizations (CDMOs), today announced the appointment of Dr. Mark Bittinger as Vice President and Global Head of Biology. Mark will be based out of the company’s new Discovery Biology facility in Cambridge, Massachusetts, USA, which provides exploratory biology capabilities to the expanding array of start-up and biotech companies in the region.

Mark Bittinger is an acknowledged leader in the area of oncology drug discovery / translational science and has over 25 years of experience across immune-oncology, epigenetics, and tumor cell metabolism. With over 20 research publications to his credit, Mark has had a stellar track record in research, innovation & cross-functional leadership in organizations such as Merck Research Labs, Dana-Farber Cancer Institute, Agios Pharmaceuticals, and Novartis Institute of BioMedical Research. Mark received his B.A. from The Johns Hopkins University and followed with a Ph.D. in Cellular & Molecular Biology from the University of Wisconsin, Madison.

Located in the heart of the Cambridge/Boston biotech ecosystem, Sai’s new 8,500 square feet lab in Kendall Square creates opportunities for biotechs to have face-to-face collaboration with Sai scientists, and to accelerate the pace of their externalized research by reducing cycle-times. The lab provides exploratory biology capabilities using state-of-the-art platforms and technologies such as high-content microscopy, CRISPR-mediated genome editing, flow cytometry/sorting, and high-throughput patch-clamp platforms to address unique client needs. These activities include new target and biomarker identification and/or validation and establishing in vitro and cell-based assays for established targets.

The Cambridge lab serves as a vital bridge, enabling seamless integration with rest of the company’s service offerings across UK and India, spanning the drug discovery and development continuum including medicinal chemistry, DMPK and toxicology, process chemistry and analytical development, and commercial scale manufacturing.

Sai Life Sciences is currently in the midst of an organization-wide initiative, Sai Nxt that is aimed at transforming the company into a new generation CDMO. With investments of over US$150 million between 2019 and 2023, the focus is on three key areas – people & culture, processes & automation, infrastructure & scientific capabilities.

Commenting on his appointment, Mark Bittinger said, " I am incredibly excited to join Sai Life Sciences as we open the doors at our new Cambridge site. Here we will deliver exploratory biology capabilities to accelerate our clients’ ability to build value and deliver tomorrow's medicines."

News

2020.06.01

Ensuring manufacturing continuity during the pandemic

Ensuring manufacturing continuity during the pandemic. Together.

‘Make it better together’ is a guiding tenet for how we operate each day. Yet, as it often does during a crisis, a truly collaborative effort during the present pandemic involving all our supply partners, airline & shipping companies, freight forwarders, transporters and our own cross-functional teams, has emphatically reinforced this belief. It has allowed […]
Read more

2020.05.07

Sai Life Sciences joins the global ‘COVID Moonshot’ project

Sai Life Sciences, today announced its collaboration with the COVID Moonshot project that aims to deliver an antiviral drug candidate effective against COVID-19. With an in-kind contribution of a team of Medicinal Chemists and supporting infrastructure, Sai Life Sciences will help synthesize and profile analogues for NCEs and other previously known compounds tested for other […]
Read more

2020.04.11

AAALAC full accreditation

AAALAC International renews full accreditation to Sai Life Sciences for its laboratory animal care and use program

As a validation of our commitment to maintaining the highest standards in animal care and compliance with industry and regulatory guidelines, the Sai Life Sciences discovery facility in Pune recently received a renewed accreditation for its laboratory animal care and use program from AAALAC (Association for the Assessment and Accreditation of Laboratory Animal Care) International. […]
Read more

2020.04.02

Sai Life Sciences becomes first India-headquartered company to join Pharmaceutical Supply Chain Initiative (PSCI)

Sai Life Sciences becomes first India-headquartered company to join Pharmaceutical Supply Chain Initiative (PSCI)

Sai Life Sciences, today announced its induction into the Pharmaceutical Supply Chain Initiative (PSCI) membership as an ‘Associate Member’. Welcoming Sai Life Sciences into its fold, a PSCI spokesperson said, “PSCI and its members are delighted to welcome Sai Life Sciences into membership, PSCI’s first member with its main headquarters in India. We are pleased […]
Read more

2020.04.01

Making sanitizers available during COVID-19 outbreak

Making sanitizers available during COVID-19 outbreak

Over the past few weeks since the outbreak of COVID-19, there’s been a sudden rise in sanitization efforts by various public and private organizations to help arrest the spread of the disease. This, along with efforts of individuals in their own spaces, has created a huge demand for effective alcohol-based sanitizers to aid the sanitization […]
Read more